← 返回

基于纳米工程平台的微环境触发免疫疗法在癌症治疗中的应用

英文原题:Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment.

查看英文原题

Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment.

PubMed 2024/10/08(内容时间) Front Biosci (Landmark Ed) Q2 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

免疫系统与癌细胞在肿瘤生长过程中相互作用复杂,免疫激活与免疫抑制之间的动态相互作用极大地影响癌症结局。NK 细胞、细胞毒性T淋巴细胞(CTLs)和树突状细胞(DC)采用多种机制来对抗癌症。

然而,慢性炎症和免疫抑制性肿瘤微环境(TME)等因素带来的挑战往往阻碍免疫细胞准确识别和清除肿瘤的能力。免疫治疗提供了一种有前景的方法,通过重编程免疫系统来靶向和清除癌细胞,同时最大限度减少副作用、增强免疫记忆,并降低转移和复发风险,优于放疗和手术等传统治疗。纳米技术通过纳米颗粒实现更安全、更高效的药物递送,提供了一种潜在解决方案。这些纳米工程药物可以定制以实现可控激活和释放。改善TME特征具有增强个性化免疫治疗和解决肿瘤部位T细胞可用性问题的潜力,尤其是在与现有疗法联合使用时。本综述讨论了TME以及克服TME中免疫抑制的策略,以及多种基于免疫细胞的策略来改善抗肿瘤反应。它还重点关注基于TME中高水平存在的因素构建微环境响应性纳米平台的策略,如酸性pH、供氧不足导致的缺氧、某些酶的高表达,以及光、超声和磁场等其他因素。联合免疫疗法与免疫治疗相结合,包括光动力疗法、光热疗法、化疗、基因治疗和放疗,与单一疗法相比,显示出高水平的抗癌活性,增强免疫原性,提高治疗效果,并降低转移。

总之,癌症免疫疗法是一种潜在的技术,可以对抗癌细胞并增强免疫系统,阻碍其生长和复发。为了预防癌症,它帮助免疫系统选择性地靶向癌细胞,并增强其长期记忆。临床试验正在扩展免疫疗法的应用,并确定改善免疫系统抗击肿瘤能力的策略。免疫疗法具有巨大的前景,为更成功的癌症治疗带来了希望。

展开英文摘要原文

The immune system and cancer cells interact intricately during the growth of tumors, and the dynamic interplay between immune activation and suppression greatly influences the cancer outcome. Natural killer cells (NK), cytotoxic T lymphocytes (CTLs) and Dendritic cells (DC), employ diverse mechanisms, to combat cancer.

However, the challenges posed by factors such as chronic inflammation and the immunosuppressive tumor microenvironment (TME) often hinder immune cells' ability to detect and eliminate tumors accurately. Immunotherapy offers a promising approach, reprogramming the immune system to target and eliminating cancer cells while minimizing side effects, enhancing immune memory, and lowering the risk of metastasis and relapse compared to traditional treatments like radiation and surgery. Nanotechnology presents a potential solution by enabling safer, more efficient drug delivery through nanoparticles. These nanoengineered drugs can be tailored for controlled activation and release. Improving TME characters holds potential for enhancing personalized immunotherapy and addressing T cell availability issues within tumor sites, particularly when combined with existing therapies.

This review discusses TMEs and the strategies to overcome immunosuppression in TME, and various immune cell-based strategies to improve antitumor response. It also focuses on the strategies for constructing microenvironment responsive nanoplatforms based upon the factors present at higher levels in TME like acidic pH, hypoxia facilitated by poor oxygen supply, higher expression of certain enzymes, and other factors such light, ultrasound and magnetic field.

Combination immune therapies combined with immunotherapy include photodynamic therapy, photothermal therapy, chemotherapy, gene therapy and radiotherapy, revealing a high level of anticancer activity in comparison to a single therapy, enhancing immunogenicity, promoting therapeutic efficacy, and lowering metastasis.

In conclusion, cancer immunotherapy is a potential technique to combat cancer cells and boost the immune system, hindering their growth and recurrence. In order to prevent cancer, it helps the immune system target cancer cells selectively and strengthens its long-term memory. Clinical trials are extending the application of immunotherapy and identifying strategies to improve the immune system tumor-fighting capabilities. Immunotherapy has enormous promise and gives hope for more successful cancer treatment.

论文信息

作者
Dhas N、Kudarha R、Kulkarni S、Soman S、Navti PD、Kulkarni J、Roy AA、Colaco V
单位
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.India
文献类型
综述
期刊
Frontiers in bioscience (Landmark edition)2024 Oct 8
原文标识
PubMed 39473401 · DOI 10.31083/j.fbl2910349